Switch theme
Sign up to access all valuation multiples
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
2005
59
LTM Revenue $14K
LTM EBITDA -$108M
$292M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Altimmune has a last 12-month revenue (LTM) of $14K and a last 12-month EBITDA of -$108M.
In the most recent fiscal year, Altimmune achieved revenue of $20K and an EBITDA of -$94.8M.
Altimmune expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Altimmune valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $14K | XXX | $20K | XXX | XXX | XXX |
| Gross Profit | $14K | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$108M | XXX | -$94.8M | XXX | XXX | XXX |
| EBITDA Margin | -780482% | XXX | -474060% | XXX | XXX | XXX |
| EBIT | -$108M | XXX | -$103M | XXX | XXX | XXX |
| EBIT Margin | -781544% | XXX | -515860% | XXX | XXX | XXX |
| Net Profit | -$99.6M | XXX | -$95.1M | XXX | XXX | XXX |
| Net Margin | -721925% | XXX | -475295% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Altimmune's stock price is $5.
Altimmune has current market cap of $440M, and EV of $292M.
See Altimmune trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $292M | $440M | XXX | XXX | XXX | XXX | $-1.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Altimmune has market cap of $440M and EV of $292M.
Altimmune's trades at 14608.6x EV/Revenue multiple, and -3.1x EV/EBITDA.
Equity research analysts estimate Altimmune's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Altimmune has a P/E ratio of -4.4x.
See valuation multiples for Altimmune and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $440M | XXX | $440M | XXX | XXX | XXX |
| EV (current) | $292M | XXX | $292M | XXX | XXX | XXX |
| EV/Revenue | 21180.3x | XXX | 14608.6x | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | -3.1x | XXX | XXX | XXX |
| EV/EBIT | -2.7x | XXX | -2.8x | XXX | XXX | XXX |
| EV/Gross Profit | 21180.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.4x | XXX | -4.6x | XXX | XXX | XXX |
| EV/FCF | -3.7x | XXX | -3.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAltimmune's last 12 month revenue growth is -68%
Altimmune's revenue per employee in the last FY averaged $0K, while opex per employee averaged $1.7M for the same period.
Altimmune's rule of 40 is -20710% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Altimmune's rule of X is -780654% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Altimmune and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -68% | XXX | -59% | XXX | XXX | XXX |
| EBITDA Margin | -780482% | XXX | -474060% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -20710% | XXX | -474128% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -780654% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 411130% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 515960% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Altimmune acquired XXX companies to date.
Last acquisition by Altimmune was XXXXXXXX, XXXXX XXXXX XXXXXX . Altimmune acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Altimmune founded? | Altimmune was founded in 2005. |
| Where is Altimmune headquartered? | Altimmune is headquartered in United States of America. |
| How many employees does Altimmune have? | As of today, Altimmune has 59 employees. |
| Who is the CEO of Altimmune? | Altimmune's CEO is Dr. Vipin K. Garg, PhD. |
| Is Altimmune publicy listed? | Yes, Altimmune is a public company listed on NAS. |
| What is the stock symbol of Altimmune? | Altimmune trades under ALT ticker. |
| When did Altimmune go public? | Altimmune went public in 2005. |
| Who are competitors of Altimmune? | Similar companies to Altimmune include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Altimmune? | Altimmune's current market cap is $440M |
| What is the current revenue of Altimmune? | Altimmune's last 12 months revenue is $14K. |
| What is the current revenue growth of Altimmune? | Altimmune revenue growth (NTM/LTM) is -68%. |
| What is the current EV/Revenue multiple of Altimmune? | Current revenue multiple of Altimmune is 21180.3x. |
| Is Altimmune profitable? | Yes, Altimmune is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Altimmune? | Altimmune's last 12 months EBITDA is -$108M. |
| What is Altimmune's EBITDA margin? | Altimmune's last 12 months EBITDA margin is -780482%. |
| What is the current EV/EBITDA multiple of Altimmune? | Current EBITDA multiple of Altimmune is -2.7x. |
| What is the current FCF of Altimmune? | Altimmune's last 12 months FCF is -$78.8M. |
| What is Altimmune's FCF margin? | Altimmune's last 12 months FCF margin is -571293%. |
| What is the current EV/FCF multiple of Altimmune? | Current FCF multiple of Altimmune is -3.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
